Press Release October 18, 2017

Medicxi Ventures-Backed Impact Raises $22.5 Million Series A Financing

Goodwin’s Life Sciences team advised Medicxi Ventures as they closed a $22.5 million Series A financing round with Impact Biomedicines. Impact Biomedicines will use the funds to launch the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. The company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule.

Medicxi Ventures manages the legacy life science portfolio of Index Ventures as well as the newly launched Medicxi 1 (MV1) and Medicxi Growth 1 (MG1) funds, which focus on investing in early stage and late-stage life sciences opportunities, respectively.

The Goodwin team was led by partner Kingsley Taft and included counsel Mulon Luo and Amoli Pandya.

For additional details on the financing, please read the press release.